Michael Okunewitch
Stock Analyst at Maxim Group
(0.93)
# 3,339
Out of 4,944 analysts
27
Total ratings
29.17%
Success rate
-11.12%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANEB Anebulo Pharmaceuticals | Downgrades: Hold | n/a | $2.40 | - | 3 | Jul 23, 2025 | |
| HCWB HCW Biologics | Maintains: Buy | $120 → $35 | $4.49 | +679.51% | 2 | May 29, 2025 | |
| CTOR Citius Oncology | Downgrades: Hold | n/a | $1.79 | - | 2 | May 23, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $5.30 | +126.42% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $4 → $7 | $0.96 | +630.69% | 2 | Feb 20, 2025 | |
| MYNZ Mainz Biomed | Initiates: Buy | $14 | $1.72 | +713.95% | 1 | Feb 14, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $1.03 | +191.26% | 1 | Jan 10, 2025 | |
| OCGN Ocugen | Initiates: Buy | $4 | $1.03 | +288.35% | 1 | Oct 15, 2024 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.59 | +1,936.66% | 1 | Sep 24, 2024 | |
| LGVN Longeveron | Maintains: Buy | $15 → $6 | $0.86 | +597.67% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $12 | $0.83 | +1,345.78% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.31 | +1,732.06% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $2.49 | +622.89% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $2.42 | +83,577.69% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $18.90 | +32.28% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.48 | +305.41% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $4.05 | +517.28% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $1.28 | +7,712.50% | 1 | Nov 30, 2021 |
Anebulo Pharmaceuticals
Jul 23, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.40
Upside: -
HCW Biologics
May 29, 2025
Maintains: Buy
Price Target: $120 → $35
Current: $4.49
Upside: +679.51%
Citius Oncology
May 23, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.79
Upside: -
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $5.30
Upside: +126.42%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $4 → $7
Current: $0.96
Upside: +630.69%
Mainz Biomed
Feb 14, 2025
Initiates: Buy
Price Target: $14
Current: $1.72
Upside: +713.95%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $1.03
Upside: +191.26%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $1.03
Upside: +288.35%
FibroBiologics
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $0.59
Upside: +1,936.66%
Longeveron
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $0.86
Upside: +597.67%
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $0.83
Upside: +1,345.78%
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $1.31
Upside: +1,732.06%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $2.49
Upside: +622.89%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $2.42
Upside: +83,577.69%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $18.90
Upside: +32.28%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $1.48
Upside: +305.41%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $4.05
Upside: +517.28%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $1.28
Upside: +7,712.50%